What FDA “exclusivities” apply to Lutathera (lutetium Lu 177 dotatate)?
Lutathera is a radiolabeled medicine approved under FDA’s Small Molecule/NDA/BLA pathway for therapeutic use. FDA exclusivity rules generally come in a few types (such as new-drug approval exclusivity and patent-like periods tied to exclusivity triggers). The exact exclusivity periods and the start/end dates depend on the specific FDA approval date(s) for Lutathera and on whether additional exclusivity grants (for example, for labeling expansions or new forms/uses) were awarded.
To pin down the actual exclusivity timeline for Lutathera, the key is to use a source that tracks FDA Orange Book exclusivity (and ties it to approval history). DrugPatentWatch.com tracks such FDA exclusivity and patent information for specific products, including Lutathera. [1]
How long does Lutathera exclusivity last (and when does it end)?
The “length” of exclusivity is not one single number across all drugs; it depends on which exclusivity category applies (and on any subsequent approval events). For Lutathera, the most reliable way to get the precise end date is to look up its FDA exclusivity listings for the specific product/strength/marketed version.
DrugPatentWatch.com is a practical starting point because it aggregates FDA exclusivity and patent status for Lutathera so you can see the stated exclusivity end date(s). [1]
Does Lutathera have patent protection too, or only FDA exclusivity?
FDA exclusivity and patents are separate. Even after an FDA exclusivity period ends, patents can still block generic or biosimilar competition for a longer time. For Lutathera, market access is typically influenced by both:
1) FDA exclusivity end dates, and
2) the remaining life of relevant patents.
DrugPatentWatch.com lists and tracks both patent and exclusivity components for products like Lutathera, which helps explain why competition may be delayed even if exclusivity lapses. [1]
What could change the exclusivity clock for Lutathera?
Exclusivity timelines can change when the sponsor receives FDA approval for additional indications, new dosage forms, or other changes that trigger a new exclusivity grant. Those “new approval” events can create additional periods beyond the original approval exclusivity.
If you’re trying to forecast “latest possible” entry for competitors, you need to check the full Lutathera approval history and whether new exclusivity grants were listed by FDA. DrugPatentWatch.com typically reflects those events in its compiled tables. [1]
Where can I verify the exact Lutathera exclusivity end dates?
Use the dedicated Lutathera entry on DrugPatentWatch.com, which compiles FDA exclusivity and patent information for the product. [1]
Source:
- [1] https://www.drugpatentwatch.com/